Bradley Foster & Sargent’s CRISPR Therapeutics CRSP Stock Holding History

Bradley Foster & Sargent’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,351	Closed	-$219K	–	430
2022 Q3	$219K	Hold	3,351	–	–	0.01%	398
2022 Q2	$204K	Hold	3,351	–	–	0.01%	424
2022 Q1	$210K	Buy	3,351 +600	+22%	+$37.7K	﹤0.01%	451
2021 Q4	$208K	Buy	2,751 +160	+6%	+$14K	﹤0.01%	434
2021 Q3	$290K	Buy	2,591 +10	+0.4%	+$1.26K	0.01%	365
2021 Q2	$418K	Buy	2,581 +120	+5%	+$14.6K	0.01%	326
2021 Q1	$300K	Buy	2,461 +11	+0.4%	+$1.66K	0.01%	336
2020 Q4	$375K	Buy	+2,450	New	+$290K	0.01%	319
2018 Q4	–	Sell	-9,460	Closed	-$420K	–	349
2018 Q3	$420K	Buy	+9,460	New	+$495K	0.01%	297
2018 Q1	–	Sell	-11,765	Closed	-$276K	–	351
2017 Q4	$276K	Buy	+11,765	New	+$224K	0.01%	317

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Bradley Foster & Sargent's CRSP Position: Q4 2022 in Review

Bradley Foster & Sargent sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 3,351 shares — an estimated $219K sold.

Bradley Foster & Sargent first reported a position in CRSP in Q4 2017 and held it in 10 quarters. The position peaked at $420K in Q3 2018. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Bradley Foster & Sargent reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Bradley Foster & Sargent sold 3,351 CRISPR Therapeutics shares in Q4 2022, an estimated $219K.
Bradley Foster & Sargent first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 10 quarters.
Bradley Foster & Sargent's CRISPR Therapeutics position peaked at $420K in Q3 2018.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Bradley Foster & Sargent's 13F filing for Q4 2022, filed 14 Feb 2023.